

1 **Nepalese version of Douleur Neuropathique 4 (DN4) questionnaire** 2 **for Assessment of Neuropathic pain: A Validation Study**

3 Bigen M Shakya,¹ Anil Shrestha,² Amod K Poudyal,³ Ninadini Shrestha,⁴ Binita Acharya,⁵ Renu
4 Gurung,⁶ Sujata Shakya⁷

5 ¹Associate Professor, bigen.shakya@mmc.tu.edu.np, Department of Anaesthesiology,
6 Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj,
7 Kathmandu, Nepal, ORCID ID: <https://orcid.org/0000-0001-5000-1595>.

8 ²Associate Professor, anil.shrestha@mmc.tu.edu.np, Department of Anaesthesiology,
9 Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj,
10 Kathmandu, Nepal.

11 ³Associate Professor, amod.poudyal@cdph.tu.edu.np, Central Department of Public Health,
12 Tribhuvan University Institute of Medicine, Kathmandu, Nepal

13 ⁴Assistant Professor, ninadinishrestha@iom.edu.np, Department of Anaesthesiology,
14 Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj,
15 Kathmandu, Nepal.

16 ⁵Associate Professor, binita.acharya@mmc.tu.edu.np, Department of Anaesthesiology,
17 Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj,
18 Kathmandu, Nepal.

19 ⁶Associate Professor, renu.gurung@mmc.tu.edu.np, Department of Anaesthesiology,
20 Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj,
21 Kathmandu, Nepal.

22 ⁷Assistant Professor, sujata_8@iom.edu.np, MPH, Central Department of Public Health,
23 Tribhuvan University Institute of Medicine, Kathmandu, Nepal, ORCID ID:
24 <https://orcid.org/0000-0003-0341-595X>.

25

26 **Word Count:** 2874

27 **Word Count of abstract:** 278

28 **Number of tables:** 6

29 **Number of figures:** 1

30 **Corresponding address:**

31 Sujata Shakya

32 99 Lagan Chowk, Ward number 21, Bagmati

33 Kathmandu, Nepal

34 Contact number: +977-9841463678

35 Email address: sujata_8@iom.edu.np

36 ORCID ID: <https://orcid.org/0000-0003-0341-595X>

37 **Abstract**

38 **Objective**

39 This study aimed to translate and validate DN4 questionnaire into Nepalese version.

40 **Design**

41 An observational study design was adopted.

42 **Setting**

43 A tertiary level teaching hospital of Kathmandu, Nepal

44 **Participants**

45 We included 166 purposively selected patients visiting pain clinics of the hospital over one year
46 time

47 **Methods**

48 The Nepalese version of the DN4 questionnaire was used to detect neuropathic pain among the
49 chronic pain patients of the hospital. The English version of the questionnaire was translated into
50 Nepali based on the standard guideline with the help of linguistic experts. The patients diagnosed
51 with nociceptive or neuropathic pain were interviewed twice in two weeks interval. We analyzed
52 test-retest reliability and strength of the test by using Intra-class correlation coefficient (ICC) and
53 Receiver Operating Characteristics (ROC) Curve, respectively. Internal Consistency reliability
54 was assessed using Cronbach's alpha (∞). Diagnostic accuracy was assessed through measures
55 like sensitivity, specificity, positive and negative predictive values, and positive and negative
56 likelihood ratio.

57

58 **Results**

59 The study showed a good test-retest reliability (ICC=0.877) and internal consistency reliability
60 (α =0.710). The AUC were 0.932 (0.894-0.971) for the first test, and 0.955 (0.921-0.990) for the
61 second test. The sensitivity and specificity values were found highest at the 4 cut-off point (4
62 score out of 10), that are 75% and 95.3% for test 1, and 76.2% and 98.8% for test 2. Similarly
63 positive and negative predictive values are 93.8% and 80.4% respectively for the first test and
64 98.4% and 81.7% respectively for the second test.

65 **Conclusions**

66 The Nepalese version of DN4 questionnaire is a valid and reliable tool for the diagnosis of
67 neuropathic pain. This can be used for screening neuropathic and non-neuropathic pain in
68 clinical as well as epidemiological settings.

69 **Key words:** Nepal; neuropathic pain; questionnaire; translate

70 **Article Summary**

71 **Strengths and Limitations of this Study**

- 72 • This study validated Nepalese version of DN4 questionnaire, so, it can be used as a
73 standard tool to assess neuropathic pain among the Nepalese population.
- 74 • As interview was conducted with the patients, this might minimize the reliability and
75 validity issue.
- 76 • This questionnaire is only applicable to those who can communicate properly in Nepalese
77 language.

- 78 • There can be problem of understanding among the participants as few words do not have
79 exact Nepali words with the same meaning.

80 **Introduction**

81 Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous
82 system (1). The diagnosis of neuropathic pain is complex, and it is based on clinical history,
83 physical examination, and other advanced investigations. Since neuropathic pain is one of the
84 prevalent health conditions, several questionnaires have been developed to facilitate its detection.
85 They include Neuropathic pain Scale (2), Pain detect (3), Leeds Assessment of Neuropathic
86 Symptoms and Signs (LANSS) (4), Douleur Neuropathique 4 (DN4). These screening tools
87 consist of structured questions and may include a simple clinical examination. The detection of
88 neuropathic pain can be done with a high degree of sensitivity and specificity with the
89 aforementioned tools (5). Moreover, these tools can be used by a specialist as well as any health
90 person (6).

91 Due to its popularity, the DN4 questionnaire has been translated and validated into various
92 languages such as Hindi (7), Thai (8), Japanese (9), Korean (10), Spanish (11), Greek (12),
93 Portuguese (13), Turkish (14) and so on. It was originally developed by French Neuropathic pain
94 group in 2005 (15). This screening tool is simple to use and can be introduced in daily practice
95 as well for epidemiological studies.

96 Translation of the standard questionnaire should preserve the meaning and intent of the original
97 item, and its validity and reliability must be maintained. The process of translation and its
98 adaptation to different cultural groups are demanding and time consuming. Without validation,
99 translation of a questionnaire may lead to misleading conclusions, either in clinical practice
100 and/or epidemiological studies. There exist guidelines for the translation and validation of tools

101 (16). Some of the standard tools, like Numerical Pain Rating Scale, have already been translated
102 and validated in Nepali language (17). Our aim is to translate and validate the DN4 questionnaire
103 according to the standard guideline. Once validated, this tool can be used as a screening tool by
104 any health personnel for the diagnosis of neuropathic pain.

105 **Methods**

106 **Study Design**

107 We conducted a prospective observational study among patients with chronic pain attending the
108 pain clinic of a tertiary level teaching hospital, Kathmandu, Nepal, over a period of one year
109 from February 2019 to January 2020.

110 **Participants Selection**

111 For the selection of participants, we adopted nonprobability purposive sampling technique and
112 included adult patients (18 years and above) who attended the pain clinic with chronic pain (pain
113 of duration more than 3 months) or who were referred from other departments for further
114 evaluation of chronic pain. Only those patients who could communicate in Nepalese language
115 were selected for the study. The excluded patients were those who had fibromyalgia, phantom
116 pain, headache, chronic visceral pain, cancer pain, and severe depression.

117 Due to the lack of consensus regarding the calculation of the sample size in validation studies,
118 the suggested ratio of subject to item ranges from 2-20 (18). The total sample size for this study
119 was 166, which was taken to make the subject-to-item ratio 16:1.

120 The ethical approval for the research was obtained from the Institutional Review Committee of
121 Institute of Medicine, Tribhuvan University [338(6-11)E²/075/76]. Written informed consent
122 was taken from the participants before data collection.

123

124

125 **Data Collection**

126 We used Nepalese version of the DN4 questionnaire among the chronic pain patients by using
127 interview technique to detect the neuropathic pain.

128 *DN4 questionnaire*

129 The DN4 questionnaire consists of 10 items, in which 7 items are related to pain characteristics
130 and 3 items are related to findings on physical examination of the painful areas. The cut-off
131 value for the diagnosis of neuropathic pain is 4/10. The area under the curve for the total score of
132 French version of the questionnaire is 0.92. A cut-off score of 4 resulted in the highest percent of
133 sensitivity (82.9%) and specificity (89.9%). The inter-rater reliability (Cohen Kappa coefficient)
134 is between 0.70 and 0.96. (15)

135 We adopted guidelines given by Sperber AD for translation process.(16)

136 *Phase 1: Translation and back-translation*

137 The English version of DN4 questionnaire was translated into Nepalese version independently by
138 three individuals, two linguistic experts, and one neurologist who had experience in management
139 of chronic pain. These three individuals along with the principal investigator then discussed
140 issues during translation process and formed a preliminary draft of Nepalese version of the
141 questionnaire. The preliminary draft so formed was back translated to English version by another
142 translation expert who was not aware of the previous translation. The committee of three pain
143 specialists (Anaesthesiologists trained in management of chronic pain), along with the forward
144 and backward translators and a research expert discussed and reviewed the items of all versions

167 **Test Methods**

168 We divided the patients with chronic pain into two groups (neuropathic and nociceptive) after
169 examination by a pain specialist in the pain clinic. The diagnosis of neuropathic pain was made
170 through the patient's history, clinical examination, and/or confirmatory tests (if applicable) based
171 on the guidelines provided by International Association for the Study of Pain (IASP) which is the
172 internationally accepted guideline (19). A pain specialist, who was not involved in the
173 segregation of patients, then performed interviews on the same day using the final corrected
174 Nepali version of DN4 questionnaire. Those patients were interviewed again within two weeks
175 using the same questionnaire during the follow-up. We considered the cutoff value for leveling
176 neuropathic pain by DN4 questionnaire as 4/10 and above. This cutoff was also originally used
177 in French version (15).

178 **Statistical Analysis**

179 We entered the data into Microsoft Excel 2013 and then exported to SPSS version 16 for
180 statistical analysis. Under descriptive statistics, mean, frequency and percentage were calculated.
181 To compare the score of DN4 questionnaire with the nature of pain, chi-square test was
182 performed. To assess the internal consistency reliability, Cronbach's alpha was calculated.
183 Cronbach's alpha of ≥ 0.7 is considered adequate. (20) We used test-retest reliability to assess
184 the correlation between two episodes of the test and derived Receiver Operating Characteristic
185 (ROC) Curve for analyzing the discriminative ability of the test. Similarly, different diagnostic
186 values to detect neuropathic pain like sensitivity, specificity, positive and negative predictive
187 value, and positive and negative likelihood ratio were calculated. Any missing or indeterminate
188 test results were excluded from the study.

189 **Patient and Public Statement**

190 No patient or public involvement was done during design, conduct, reporting or dissemination of
191 the research. The patients attending pain clinic were involved as participants after obtaining
192 written informed consent.

193 Results

194 The total participants attending the pain clinic during the period of the study was 216. Out of
195 these, 50 patients were excluded due to various reasons like cancer, headache, pain less than 3
196 months, phantom pain, and visceral pain. Thus, the total number of eligible participants enrolled
197 in this study was 166.

198 The general characteristics of the respondents are presented in Table 1. The mean ages of the
199 patients with nociceptive pain and neuropathic pain were 49.03±15.1 and 52.79±14.8 years
200 respectively. More than two-third (67.4%) were females.

201 **Table 1. Baseline Characteristics**

Characteristics		Nociceptive (n=86)		Neuropathic (n=80)	
Age (in years)	Mean age	49.03±15.1		52.79±14.8	
Sex	Male	28 (32.6%)		31 (38.8%)	
	Female	58 (67.4%)		49 (61.3%)	

202 The most common symptoms in patients with neuropathic pain were tingling sensation (75.0%),
203 burning pain (72.5%), needle sensation (71.3%), and electrical pain (71.3%) (Table 2). These
204 symptoms were found significantly more among patients with neuropathic pain compared to
205 those with nociceptive pain (p<0.001).

206 **Table 2: Comparison of Items of DN4 Questionnaire between Neuropathic and**
207 **Nociceptive conditions**

Items	Nociceptive (n=86)				Neuropathic (n=80)				p value*
	Absent		Present		Absent		Present		
	n	%	n	%	n	%	n	%	

Burning	61	70.9	25	29.1	22	27.5	58	72.5	<0.001
Cold pain	79	91.8	7	8.1	66	82.5	14	17.5	0.7
Electric pain	74	86.0	12	14.0	23	28.8	57	71.3	<0.001
Tingling	66	76.7	20	23.3	20	25.0	60	75.0	<0.001
Needle sensation	56	65.1	30	34.9	23	28.8	57	71.3	<0.001
Numbness	81	94.2	5	5.8	45	56.3	35	43.8	<0.001
Itching	85	98.8	1	1.2	66	82.5	14	17.5	<0.001
Decreased sense on touch	84	97.7	2	2.3	53	66.3	27	33.8	<0.001
Decreased sense on pin pick	86	100.0	0	0	56	70.0	24	30.0	<0.001
Increased pain on brushing	83	96.5	3	3.5	55	68.8	25	31.3	<0.001

208 *Chi-square test

		Diagnosis of pain				p value*
		Nociceptive (n=86)		Neuropathic (n=80)		
		n	%	n	%	
DN4 first time	Negative	82	80.4	20	19.6	<0.001
	Positive	4	6.3	60	93.8	
DN4 second time	Negative	85	81.7	19	18.3	<0.001
	Positive	1	1.6	61	98.4	

209 Table 3 compares the pain assessment using DN4 questionnaire with the diagnosis of pain. It
 210 shows a highly significant association between the two scores of DN4 questionnaire and the
 211 actual diagnosis of pain (p<0.001).

212 **Table 3. Comparison of the score of DN4 questionnaire with diagnosis of pain**

213 *Chi-square test

214 **Internal Consistency Reliability (Chronbach's alpha)**

215 The Cronbach's alpha (∞) coefficient of the entire DN4 questionnaire is found to be 0.710,
 216 indicating adequate internal consistency. The coefficient value was not much difference by
 217 removing any of the items in the questionnaire. Thus, all questions were included in the DN4
 218 questionnaire (Table 4).

219 **Table 4: Internal Consistency Reliability**

Item	Cronbach's ∞	ICC (95% CI)	Cronbach's ∞ (if single item deleted)
Burning	0.710	0.640-0.772	0.689
Cold pain			0.728
Electric pain			0.677
Tingling			0.656
Needle sensation			0.710
Numbness			0.664
Itching			0.701
Decreased sense on touch			0.660
Decreased sense on pin pick			0.661
Increased pain on brushing			0.719

220 ICC = Intra-class Correlation Coefficient

221 **Test-retest Reliability**

	Test (Mean \pm SD)	Re-test (Mean \pm SD)	ICC (95% CI)
Retest sample (n=166)	3.06 \pm 2.293	2.74 \pm 2.235	0.948 (0.921-0.964)*
NP (n=80)	4.79 \pm 1.874	4.55 \pm 1.764	0.877 (0.807-0.921)*
NNP (86)	1.45 \pm 1.233	1.06 \pm 0.925	0.858 (0.689-0.925)*

222 The patients were interviewed twice using the Nepalese version of DN4 questionnaire, once
 223 during their first visit at the pain clinic, and again within 2 weeks. The test-retest reliability was
 224 measured by calculating intra-class correlation coefficient, which was found to be more than 0.8,
 225 indicating a good test-retest reliability value (Table 5).

226 **Table 5: Test-retest reliability of the Nepali version of the DN4 questionnaire**

227 NP = Neuropathic Pain, NNP = Non-neuropathic Pain, ICC = Intra-class Correlation Coefficient, *p<0.001 (p value
 228 for intra-class correlation coefficient)

229 **Receiver Operating Characteristics Curve (ROC) Analysis**

230 The clinical diagnosis was used as the reference for the calculation of Area under the Curve
 231 (AUC). Figure 1 represents the ROC curve for two episodes of the test using Nepali version of
 232 DN4 questionnaire. The AUCs for the two episodes of test were 0.932 with 95% CI (0.894 to
 233 0.971) and 0.955 with 95% CI (0.921-0.990), which signifies a strong test.

234 The sensitivity and specificity values for the two episodes of the test were found highest at the
235 cut-off level of 4, which was also used in the original DN4 questionnaire. Similarly, other
236 measures like Youden index, positive and negative predictive values, etc were also calculated
237 (Table 6).

238

239

240 **Table 6. Diagnostic Values of the DN4 questionnaire for the Discrimination of Neuropathic**
241 **Pain**

Test Result	Youden index	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	PLR (%)	NLR (%)
Test 1	0.7	75.0	95.3	93.8	80.4	15.96	0.26
Test 2	0.75	76.2	98.8	98.4	81.7	63.5	0.24

242 PPV: Positive Predictive Value, NPV: Negative Predictive Value, PLR: Positive Likelihood Ratio, NLR: Negative
243 Likelihood Ratio

244

245 Discussion

246 This study was conducted at one of the academic institutes of Nepal among 166 patients who
247 were referred to the pain clinic. The Nepali version of DN4 questionnaire was tested on the
248 patients. The test-retest reliability was determined, along with AUC analysis and calculation of
249 sensitivity, specificity, positive and negative predictive values with a cutoff value of 4, which
250 was also originally used in French version (15). DN4 questionnaire was first created by French
251 neuropathic team and was originally in French language. Due to its simplistic nature, the
252 questionnaire has been translated into various other languages. However, translation can be a
253 complicated process. The major hurdle is the fact that every language has its own unique
254 nuances, grammatical rules, vocabulary, and so on. Rendering ideas from one language to
255 another while also keeping the essence intact is a difficult task with a simple translation. The

256 issues that could be encountered during translation of questionnaires were well discussed in the
257 study by Seventer et al. (21). The authors described three situations: the original word can be
258 literally translated, the word might need added explanation, or a different word that retains the
259 intended meaning has to be used. For interpreting this questionnaire into Nepali language, we
260 have conformed to the universal guidelines for translating questionnaires.

261 The first time we encountered a problem was while we were trying to restate questions 1 and 2 in
262 Nepali. [Question 1: Does the pain have one or more of the following characteristics? Question
263 2: Is the pain associated with one or more of the following symptoms in the same area?] Due to
264 the inherent discrepancies in the grammatical rules and lexicons of the two languages, achieving
265 a direct rendering of the aforementioned questions proved infeasible. With the aid of two
266 interpreters and clinical staff, we managed to come up with restatements that are close in
267 meaning to the original questions, but also in line with the conventions of the Nepali language
268 which Nepalese people can easily comprehend. Of all the items listed in the questionnaire, ‘cold
269 pain’ was the most difficult term to properly translate. All other items except this term have
270 Nepali equivalents. For this reason, we had to think of a phrase that conveyed the same meaning
271 as ‘cold pain’. Most of the patients in the study actually believed that this kind of pain is
272 aggravated by cold weather. Upon asking the question “Do you understand what it means?”, we
273 identified this common misconception. For this reason, caution must be exercised while asking
274 the patient about cold pain. In the Hindi version of DN4 questionnaire also, cold pain was
275 present in only 14% of patients with neuropathic pain (7). In our study, only 17 % of patients
276 with neuropathic pain had symptoms of cold pain.

277 While interviewing twice using the Nepali version of the questionnaire, it showed a good test-
278 retest reliability value (ICC=8). In the same way, the New Arabic version (22) of the

279 questionnaire also showed excellent test-retest reliability ($ICC > 0.9$). The test-retest intraclass
280 correlation coefficient (95% CI) of the Japanese version was 0.827 (0.769–0.870) (9). Similarly,
281 in our study, the AUC values for tests 1 and 2 were 0.932 with 95% CI (0.894-0.971) and 0.955
282 with 95% CI (0.921-0.990) respectively. The sensitivity and specificity of our version of the
283 questionnaire were 75% and 95.3%, respectively, for test 1, and 76.2% and 98.8%, respectively,
284 for test 2, which were the highest at the cut-off value 4 or more. This finding is in accordance
285 with most of the validation studies (7,9,11). There are, however, validations done in Dutch (23)
286 and New Arabic (22) languages, and both found the cutoff value at 5/10.

287 Based on our study, the most frequent complaints that patients with neuropathic pain had were
288 burning pain, electrical sensation, tingling sensation, and numbness. When this is compared with
289 other studies, we found variations (7,22,23). We believe that neuropathic pain consists of a
290 collection of symptoms and signs that may also depend on the type of disease, so rather than
291 focusing on any specific item for predicting neuropathic pain, one must consider the cutoff value.
292 As per our study, a cutoff point of 4/10 is the best for predicting neuropathic pain.

293 Our sample consisted of both literate and illiterate patients (those who could communicate in
294 Nepali language). However, we did not face any difficulties during the interviews, and the results
295 were also very similar. This study can validate Nepali version of DN4 questionnaire so that it can
296 be used as a standard tool to assess neuropathic pain among the Nepalese population. As the
297 interview was conducted with the patients, this minimizes the reliability and validity issue that
298 can occur in the case of a self-administered questionnaire. However, there were few limitations
299 too. The patients were first seen by a pain physician who was not involved in the interview. He
300 used clinical judgment for clinical diagnosis of pain. Other investigations could not be carried
301 out due to financial constraints of the patients. Importantly, the institutional policy did not permit

302 such investigations just for the sake of research. The same clinical diagnosis was used as
303 reference for the calculation of the data. Besides, Nepal is a small country, but with multicultural
304 and multilinguistic population. Thus, this questionnaire is only applicable to those who can
305 communicate properly in Nepali language. There can be a problem of understanding among the
306 participants as few words do not have an exact Nepali language with the same meaning, for
307 instance, ‘cold pain’.

308 **Conclusion**

309 The Nepalese version of DN4 questionnaire has been validated and can be used as a screening
310 tool for predicting neuropathic pain in patients with chronic pain who can communicate well in
311 Nepali.

312 **Acknowledgements**

313 We would like to thank Mr. Laxman Rajbanshi (MA in Political Science) and Mr. Tirtha Ratna
314 Shakya (MA) and Dr. Sarbottan Shrestha (Neurologist) for translating the questionnaire into
315 Nepali and Mr. Sandesh Shakya (MA in English) for back translation. We would also like to
316 thank the hospital and the patients who participated in the study

317 **Author Contributions**

318 The corresponding author attests that all the following listed authors meet authorship criteria, and
319 no others meeting the criteria have been omitted.

320 BMS: study concept and design, literature review, manuscript writing, review and editing

321 AS: literature review, manuscript review

322 AKP: data analysis, manuscript review

323 NS: data collection, literature review, manuscript review

324 BA: data collection, literature review, manuscript review

325 RG: data collection, literature review, manuscript review

326 SS: data analysis, manuscript writing and editing

327

328

329 **Funding**

330 This research received no specific grant from any funding agency in the public, commercial, or
331 non-profit sectors.

332 **Competing Interests**

333 None declared

334 **Patient consent for publication**

335 Not required

336 **Ethical approval**

337 The ethical approval for the study was obtained from the Institutional Review Committee of,
338 Tribhuvan University, Institute of Medicine, Nepal (338(6-11)E²/075/76).

339 **Data availability statement**

340 The raw data can be made available upon genuine request.

341 **Supplementary Material**

342 The supplementary file consists of STARD checklist showing whether the required information
343 has been included in manuscripts submitted for publication. It also includes the diagram showing
344 the flow of participants through the study.

345 **References**


- 346 1. IASP. IASP Terminology [Internet]. 2017 [cited 2019 Oct 10]. Available from:
347 <https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698>
- 348 2. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific
349 to neuropathic pain: The Neuropathic Pain Scale. *Neurology*. 1997;48(2):332–8.
- 350 3. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: A new screening
351 questionnaire to identify neuropathic components in patients with back pain. *Curr Med*
352 *Res Opin*. 2006;22(10):1911–20.
- 353 4. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of
354 predominantly neuropathic origin: Validation for use in clinical and postal research. *J*
355 *Pain*. 2005;6(3):149–58.
- 356 5. Mathieson S, Maher CG, Terwee CB, Folly De Campos T, Lin CWC. Neuropathic pain
357 screening questionnaires have limited measurement properties. A systematic review. *J*
358 *Clin Epidemiol* [Internet]. 2015;68(8):957–66. Available from:
359 <http://dx.doi.org/10.1016/j.jclinepi.2015.03.010>
- 360 6. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using
361 screening tools to identify neuropathic pain. *Pain*. 2007;127(3):199–203.
- 362 7. Gudala K, Ghai B, Bansal D. Hindi version of short form of douleur neuropathique 4 (S-

- 363 DN4) questionnaire for assessment of neuropathic pain component: A cross-cultural
364 validation study. *Korean J Pain*. 2017;30(3):197–206.
- 365 8. Chaudakshetrin P, Prateepavanich P, Chira-Adisai W, Tassanawipas W, Leechavengvongs
366 S, Kitisomprayoonkul W. Cross-cultural adaptation to the Thai language of the
367 neuropathic pain diagnostic questionnaire (DN4). *J Med Assoc Thail*. 2007;90(9):1860–5.
- 368 9. Matsuki Y, Sukenaga N, Miyagi K, Tsunetoh T, Mizogami M, Shigemi K, et al.
369 Reliability and validity of the Japanese translation of the DN4 Diagnostic Questionnaire in
370 patients with neuropathic pain. *J Anesth [Internet]*. 2018;32(3):403–8. Available from:
371 <https://doi.org/10.1007/s00540-018-2495-7>
- 372 10. Kim HJ, Park JH, Bouhassira D, Shin JH, Chang BS, Lee CK, et al. Validation of the
373 Korean version of the DN4 diagnostic questionnaire for neuropathic pain in patients with
374 lumbar or lumbar-radicular pain. *Yonsei Med J*. 2016;57(2):449–54.
- 375 11. Perez C, Galvez R, Huelbes S, Insausti J, Bouhassira D, Diaz S, et al. Validity and
376 reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions)
377 questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or
378 somatic component. *Health Qual Life Outcomes*. 2007;5:1–10.
- 379 12. Sykioti P, Zis P, Vadalouca A, Siafaka I, Argyra E, Bouhassira D, et al. Validation of the
380 Greek Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain. *Pain Pract*.
381 2015;15(7):627–32.
- 382 13. Santos JG, Brito JO, de Andrade DC, Kaziyama VM, Ferreira KA, Souza I, et al.
383 Translation to Portuguese and Validation of the Douleur Neuropathique 4 Questionnaire. *J*
384 *Pain*. 2010;11(5):484–90.

- 385 14. Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS
386 questionnaires in the assessment of neuropathic pain: Validity and reliability of the turkish
387 version of DN4. *J Pain* [Internet]. 2010;11(11):1129–35. Available from:
388 <http://dx.doi.org/10.1016/j.jpain.2010.02.003>
- 389 15. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of
390 pain syndromes associated with nervous or somatic lesions and development of a new
391 neuropathic pain diagnostic questionnaire (DN4). *Pain*. 2005;114(1–2):29–36.
- 392 16. Sperber AD. Translation and Validation of Study Instruments for Cross-Cultural
393 Research. *Gastroenterology*. 2004;126(1):124–8.
- 394 17. Sharma S, Palanchoke J, Reed D, Haxby Abbott J. Translation, cross-cultural adaptation
395 and psychometric properties of the Nepali versions of numerical pain rating scale and
396 global rating of change. *Health Qual Life Outcomes*. 2017;15(1):1–11.
- 397 18. Anthoine E, Moret L, Regnault A, Sbille V, Hardouin JB. Sample size used to validate a
398 scale: A review of publications on newly-developed patient reported outcomes measures.
399 *Health Qual Life Outcomes*. 2014;12(1):1–10.
- 400 19. Finnerup N, Haroutounian S, Kamerman P, Baron R, Bennett D, Bouhassira D, et al.
401 Neuropathic pain: an updated grading system for research and clinical practice. *Essence*
402 *Analg Analg*. 2010;157(8):30–7.
- 403 20. Nunnally J. *Psychometric Theory*. New York: McGraw-Hill; 1978.
- 404 21. Seventer R, Vos C, Meerding W, Mear I, Gal M, Bouhassira D, et al. Linguistic validation
405 of the DN4 for use in international studies. *Eur J Pain* [Internet]. 2010;14(1):58–63.

- 406 Available from: <http://dx.doi.org/10.1016/j.ejpain.2009.01.005>
- 407 22. Chatila N, Pereira B, Maarrawi J, Dallel R. Validation of a New Arabic Version of the
408 Neuropathic Pain Diagnostic Questionnaire (DN4). *Pain Pract.* 2017;17(1):78–87.
- 409 23. Timmerman H, Steegers MAH, Huygen FJPM, Goeman JJ, Van Dasselaar NT, Schenkels
410 MJ, et al. Investigating the validity of the DN4 in a consecutive population of patients
411 with chronic pain. *PLoS One.* 2017;12(11):1–21.
- 412
- 413
- 414

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .



AUC (Test 1) = 0.932 (95% CI: 0.894-0.971)

AUC (Test 2) = 0.955 (95% CI: 0.921-0.990)

Figure 1. Receiving-operator characteristic (ROC) curve for the total score of DN4